No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VSTM240719C3000
- 0.75
- -0.35-31.82%
15min DelayClose Jul 12 15:59 ET
0.75High0.30Low
0.30Open1.10Pre Close7 Volume72 Open Interest3.00Strike Price350.00Turnover208.32%IV11.61%PremiumJul 19, 2024Expiry Date0.36Intrinsic Value100Multiplier6DDays to Expiry0.39Extrinsic Value100Contract SizeAmericanOptions Type0.7054Delta0.3548Gamma5.84Leverage Ratio-0.0249Theta0.0003Rho4.12Eff Leverage0.0016Vega
Intraday
- 5D
- Daily
News
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%.The iShares Biotechnology ETF (IBB) gained 0.8%
Sector Update: Health Care
Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 1% and the Health Care Select Sector SPDR Fund (XLV) up 0.9%.The iShares Biotechnology ETF (IBB) gained 1%.
Verastem Spikes as Dosing for Lead Program Starts in China
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share.ASP Isotopes
Express News | Verastem Shares Are Trading Higher After the Company Announced the First Patient Has Been Dosed in a Phase 1/2 Trial in China, Conducted by GenFleet Therapeutics, Evaluating GFH375/VS-7375, a KRAS G12D Inhibitor
Express News | Verastem Inc: To Initiate Development Studies Outside of China After Evaluating Initial Dose Escalation Data From Phase 1 Study in China
Comments
$Verastem(VSTM.US$ target price is $18. i hope this run!
1
$Verastem(VSTM.US$
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375...
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375...
1
$Verastem(VSTM.US$ Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $18
储亿银行维持Verastem(VSTM.US)买入评级，目标价18美元
储亿银行维持Verastem(VSTM.US)买入评级，目标价18美元
1
1
1
1
$Verastem(VSTM.US$ one solid month of grinding lower and lower. I know the MMs are short on this but are there any shares left to sell at all? 🤷🏾♂️
Support and Resistance have become meaningless on this stock. 🤦🏾♂️
Support and Resistance have become meaningless on this stock. 🤦🏾♂️
Read more